New drug cocktail aims to keep relapsed myeloma in check
NCT ID NCT03030261
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II study tests whether a combination of elotuzumab, pomalidomide, and dexamethasone can help control relapsed multiple myeloma after a second stem cell transplant. The trial enrolls 25 adults whose myeloma returned after their first transplant. Participants receive the drug combo as maintenance therapy to delay further relapse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
elotuzumab, pomalidomide, and dexamethasone
What this could lead to
If successful, this combination therapy could improve control of relapsed multiple myeloma and extend the time before the disease progresses again.
What could go wrong
This is a small, early-phase study with only 25 participants, so results may not apply to everyone. The drugs can cause side effects like low blood counts, infections, and fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colorado Blood Cancer Institute (Sarah Cannon)
Denver, Colorado, 80218, United States
-
University Health Network - Princess Margaret Cancer Centre
Toronto, Ontario, M5G 2M9, Canada
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States